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The A/swan/Poland/305-135V08/2006 (H5N1-subtype) 
hemagglutinin (HA) gene was cloned and expressed in 
yeast Pichia pastoris (P. pastoris). The HA cDNA lacking 
the C-terminal transmembrane anchor-coding sequence 
was fused to an α-factor leader peptide and placed 
under control of the methanol-inducible P. pastoris alco-
hol oxidase 1 (AOX1) promoter. Two P. pastoris strains: 
SMD 1168 and KM 71 were used for protein expression. 
Recombinant HA protein was secreted into the culture 
medium reaching an approximately 15 mg/L (KM 71 
strain). Fusion protein with a His6 tag was purified to 
homogeneity in one step affinity chromatography. SDS-
PAGE and MS/MS analysis indicated that the protein is 
cleaved into HA1 and HA2 domains linked by a disulfide 
bond. Analysis of the N-linked glycans revealed that the 
overexpressed HA is fully glycosylated at the same sites 
as the native HA in the vaccine strain. Immunological ac-
tivity of the hemagglutinin protein was tested in mice, 
where rHA elicited a high immune response.
Key words: Avian influenza, H5N1, recombinant hemagglutinin, Pi-
chia pastoris
INTRODUCTION
Methylotrophic yeast Pichia pastoris efficiently express-
es recombinant genes. Pichia has the following main 
advantages: (i) it is able to express heterologous genes 
in high yield (Romanos, 1995; Rodriguez et al., 1998), 
(ii) the proteins produced in this system may be secret-
ed into the culture medium preserving correctly formed 
disulfide bonds (White et al., 1994). Additionally, P. pas-
toris secretes only a few other proteins to the medium 
which facilitates protein purification. (iii) The carbohy-
drate cores incorporated into the N-glycosylation sites 
(Asn-X-Ser/Thr) of recombinant protein molecules are 
frequently at similar positions to those found in natural 
glycoproteins. Outer sugar of P. pastoris secreted proteins 
is Man8-10 GlcNAc2 (Grinna & Tschopp, 1989). Effi-
ciency of the P. pastoris expression system is based on 
an unusually strong promoter from the alcohol oxidase 1 
gene (AOX1) driving the expression of the foreign gene. 
The AOX1 promoter is repressed in cells grown on glu-
cose and most other carbon sources, but is induced over 
1000-fold when cells are shifted to a medium containing 
methanol as a sole carbon source (Careghino et al., 2002). 
Nowadays, Pichia is widely accepted as an important bio-
technological host organism. Various pharmacological-
ly important proteins were produced in this expression 
system e.g: malaria vaccine antigen (Brady et al., 2001), 
human serum albumin (Bushell et al., 2003), IGF-1 (Bre-
rley, 1998), insulin (Kjeldsen et al., 1999) and hepatitis B 
antigen (Cregg et al.,1987). This study is aimed at expres-
sion of the hemagglutinin (HA) gene of H5N1 avian in-
fluenza virus (AIV) in Pichia cells. The HA protein plays 
a crucial role in the virus infection. HA glycoprotein is 
synthesized as an inactive HA0 molecule assembled as 
noncovalently bound homotrimers on the viral surface. 
This precursor protein is cleaved (RRKKR/G multi-ba-
sic cleavage site for H5 subtype) by trypsin-like proteases 
to create two subunits, HA1 and HA2 which are linked 
by a single disulfide bond (Skehel & Wiley, 2000). After 
cleavage, at the specific site, these two disulfide-bonded 
protein domains produce the mature form of the HA 
protein. Cleavage is a prerequisite for the infection. The 
HA0 molecule is post-translationally modified by glyco-
sylation. Glycans are attached via N-glycosilic linkages 
to the asparagine residue of the conserved glycosylation 
site motif Asn-X-Ser/Thr (X-any amino acid) (Grinna & 
Tschopp, 1989).
There are several strategies to develop a new genera-
tion of vaccines. One of the simplest is using the surface 
proteins of the virus. It was demonstrated that HA is 
the major target for the development of influenza vac-
cines (Crawford et al., 1999; Athmaram et al., 2011). In 
this report, we describe expression of the HA gene of 
H5N1 avian influenza virus in Pichia pastoris system. rHA 
was produced in a soluble form with high yield and was 
shown to be highly immunogenic in mice.
MATERIALS AND METHODS
Strain and plasmid vector. Two P. pastoris strains: 
KM 71 (his4, aox1::ARG4) and the protease deficient 
SMD 1168 (his4 and pep4), and the yeast expression 
pPICZαC vector were obtained from Invitrogen.
Construction of pPICZαC/HAHis6 vector and 
transformation of Pichia pastoris. The IV strain H5N1 
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A/swan/Poland/305-135V08-2008 was the source of 
HA gene. The DNA fragment encoding HA protein 
lacking 16 N-terminal aminoacids and C-terminal trans-
membrane anchor and cytoplasmic domain was ampli-
fied using forward and reverse primers containing ClaI 
and NotI restriction sites, respectively, and pGEM/HA 
as the template. The modified fragment codes for HA 
truncated peptide. Appropriate PCR fragment was insert-
ed into pPICZαC plasmid and introduced into P. pas-
toris strain KM73 or SMD 1168 by electroporation as 
described in the Invitrogen manual. Yeast transformants 
were also screened for the construct insertion at the al-
cohol oxidase promoter (AOX I) site by PCR, using 5’ 
AOX I and 3’ AOX I primers (Invitrogen).
Cell growth. Insert-positive yeast clones were grown 
initially in 100 or 400 ml of BMGY medium (1% yeast 
extract, 2% peptone, 100 mM potassium phosphate, pH 
6.0, 1.34% yeast nitrogen base, 4 × 10–5 % biotin, and 1% 
glycerol) at 30°C on a plate agitator at 160 rpm agita-
tion. When the culture reached OD600 of 2, the cells 
were centrifuged at 3000 × g for 5 min and resuspended 
in one/ fourth of the original volume of BMMY me-
dium (1% yeast extract, 2% peptone, 100 mM potassium 
phosphate, pH 7.8, 1.34% yeast nitrogen base, 4×10–5% 
biotin, and 5% methanol) for induction of the AOX I 
promoter. Subsequent incubation at 26°C with vigor-
ous shaking was continued for 5 or 7 days. The culture 
medium was cleared of yeast cells by centrifugation at 
3000 × g at 4°C for 6 min and the supernatant was col-
lected for further HA purification.
Purification of His6-rHA. Recombinant protein 
containing the hexahistidine tag was purified by affin-
ity chromatography on Ni-NTA resin (Qiagen). 100 ml 
of post culture medium aliquot was diluted to 200 ml 
with a PBS buffer pH 7.4 containing 500 mM NaCl and 
gently mixed with 3 ml Ni-NTA resin at 4°C for 2.5 h. 
The resin was packed into a column and washed with 
one volume of PBS buffer, then the bound protein was 
eluted with 3 ml portions of the elution buffer (250 mM 
imidazole in PBS). Fractions containing protein were 
analyzed by SDS/PAGE and Western blotting. All frac-
tions containing purified protein were pooled and dia-
lyzed against PBS buffer pH 7.4. Subsequently the pro-
tein was lyophilized and stored at –80°C.
Western blotting. Proteins separated by 12% SDS/
PAGE were electrotransferred onto an Immobilon-P 
transfer membrane (Millipore). The membrane was incu-
bated for 2 h with 5% non-fat dried milk in a TBS-T 
buffer (10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 0.05% 
Tween 20). His6-tagged HA protein was detected using 
a mouse monoclonal anti-His-HRP antibody (1:5000, 
Abcam). The membrane was analyzed using SuperSignal 
West Femto Trial Kit (Thermo Scientific). His6-tagged 
HA protein was also detected with monoclonal anti-HA1 
antibody (a gift from the Institute of Biotechnology and 
Antibiotics, Warsaw). Alkaline phosphatase-conjucated 
anti-mouse antibody was used as a secondary antibody 
diluted at 1:30 000 (Sigma-Aldrich). The blot was visual-
ized with Western Blue Stabilized Substrate for alkaline 
phosphatase (Promega).
Determination of protein concentration. Protein 
concentration was determined according to the Bradford 
protocol. Bovine serum albumin was used as the stand-
ard.
Enzymatic deglycosylation. 5 μg of rHA protein 
was denatured with 1x Glycoprotein Denaturizing Buffer 
at 95°C for 10 min. 20 μl of reaction mix containing de-
natured HA protein and 0.125 U of endoglycosidase H 
(Endo H, NEB) in 1× G5 reaction buffer (50 mM so-
dium citrate, pH 5.5) was incubated at 37°C for 1 h. An 
untreated protein sample was incubated under the same 
conditions without the enzyme.
MS/MS analysis of rHA. rHA protein after reaction 
with Endo H was analyzed by SDS/PAGE. A gel band 
containing deglycosylated polypeptides was excised. Pro-
tein was reduced with 100 mM DTT (for 30 minutes at 
56°C), alkylated with 0.5 M iodoacetamide (45 min in a 
dark at room temperature) and digested overnight with 
12.5 ng/μl of trypsin (sequencing Grade Modified Tryp-
sin — Promega V5111) by adding the enzyme directly to 
the reaction mixture. Peptides were analyzed by LC-MS-
MS/MS (liquid chromatography coupled to tandem mass 
spectrometry) using Nano-Acquity (Waters) LC system 
and Orbitrap Velos mass spectrometer (Thermo Elec-
tron Corp.), by applying peptides to RP-18 precolumn 
(nanoACQUITY Symmetry® C18 — Waters 186003514) 
using water containing 0.1% TFA as a mobile phase and 
then transferred to nano-HPLC RP-18 column (nano-
ACQUITY BEH C18 — Waters 186003545) using an 
acetonitrile gradient (0–35 % AcN in 180 minutes) in 
the presence of 0.05% formic acid with the flow rate 
of 250 nl/min. Column outlet was directly coupled to 
the ion source of the spectrometer working in the re-
gime of data dependent MS to MS/MS switch. A blank 
run ensuring lack of cross contamination from previous 
samples preceded each analysis. Acquired raw data were 
processed by Mascot Distiller followed by Mascot Search 
(Matrix Science, London, UK, on-site license) against 
users’ defined database. Search parameters for precur-
sor and product ions mass tolerance were 40 ppm and 
0.8 Da, respectively, enzyme specificity: trypsin, missed 
cleavage sites allowed: 1, fixed modification of cysteine 
by carbamidomethylation and variable modification of 
methionine oxidation and HexNAc at asparagine. Pep-
tides with Mascot Score exceeding the threshold value 
corresponding to < 5% False Positive Rate, calculated 
by Mascot procedure were considered to be positively 
identified. Fragmentation spectra of peptides indicated 
by Mascot as N-glycosylated were manually investigated.
Immunization experiments. Seven-week old, patho-
gen-free, female Balb/c mice were used for vaccination. 
The animals were housed in a temperature controlled 
enviroment at 24°C with 12 h day-night cycles and re-
ceived food and water ad libidum. Immunization experi-
ments were done with groups consisting of 5 or 7 mice, 
in the animal house of Institute of Experimental Medi-
cine PAS (Warsaw) under control of the Bioethics Com-
mittee (permission no 11/2012). In the first experiment 
mice were immunized three times intradermally in the 
hind paw at 3-week intervals with 100 μl containing 1, 
5 or 25 ug of HA. An adequate portion of the protein 
was dissolved in saline plus adjuvant. For immunization, 
25 μg of Sigma Adjuvant System containing 0.5 mg Mo-
nophosphoryl Lipid A (detoxified endotoxin) from Sal-
monella minnesota and 0.5 mg synthetic Trehalose Dico-
rynomycolate in 2% oil (squalene)-Tween® 80-water was 
used. Two booster injections were adjuvated with 25 μg 
monophosphoryl lipid A and 25 μg muramyl dipeptide 
(Sigma-Aldrich). Control mice received adjuvant only. 
One week prior to the first immunization and 2 weeks 
after each immunization, blood samples were collected, 
allowed to coagulate and centrifuged. The collected sera 
were stored at –20°C before measuring the antibody lev-
el. In the second experiment, two different methods of 
administration were applied. Mice were immunized intra-
dermally in the hind paw and subcutaneously in the neck 
with 100 μl of 25 μg rHA plus adjuvant. The immuniza-
tion scheme was identical as in the first experiment.
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ELISA test. Sera from experimental animals were an-
alyzed by indirect ELISA for detection of anti-HA IgG 
antibodies. The 96-well polystyrene plates (Nunc) were 
coated overnight at 4°C with recombinant H5 HA (17-
530, Δ341-346, 6xHis-tag at C-terminus) antigens: HA 
(A/Bar-headed Goose/Qinghai/12/05(H5N1)) pro-
duced in a mammalian cell system (Immune Technolo-
gy) and HA (A/swan/Poland/305-135V08/2006(H5N1)) 
produced in a baculovirus system (Oxford Expression 
Technologies), diluted in PBS to 1 µg/ml for coating 
MaxiSorp wells (mouse trial 1) and 6 µg/ml for coat-
ing MediSorp wells (mouse trial 2), respectively. On the 
next day, plates were washed with PBST, blocked for 
1.5 h with 2% BSA/PBS at 37°C. Bound IgG were de-
tected using goat anti-mouse IgG (γ-chain specific)-HRP 
antibodies (Sigma-Aldrich). After incubation with TMB 
chromogen substrate solution (Sigma-Aldrich), absor-
bance was measured at 450 nm with a microplate reader 
(Synergy 2; BioTek Instruments).
Hemagglutinin Inhibition (HI) test. Sera samples 
were heat inactivated at 56°C for 30 min. and then were 
pretreated by kaolin and chicken erythrocytes to avoid 
a false positive reaction in the HI test (Bizanov & Ta-
mosiunas, 2005). The pretreated sera (25 µl of sera in 
serial twofold dilutions) were incubated for 25 min in a 
titration plate with 4 HA units of the inactivated antigen 
(Bizanov and Tamosiunas, 2005). Next, the suspension 
of 1% hen’s erythrocytes was added and incubated for 
30 min. The HI titer was determined as the reciprocal 
of the highest dilution in which hemagglutination is in-
hibited. Samples were assigned as positive when their ti-
ter was ≥ 16. Sera from the immunization experiments 
(Trials 1 and 2) were tested using a heterologous strain 
H5N2 A/chicken/Belgium/150/1999 virus (GD Deven-
ter).
Accession numbers. Sequences used in this study 
are available in public databases: H5N1 A/swan/
Poland/305-135V08/2006 (EpiFluDatabase [http://plat-
form.gisaid.org], GenBank Accession No. EP1156789).
RESULTS
Protein expression and purification
In order to evaluate the potential of P. pastoris as an 
expression host for production of a recombinant influen-
za H5 hemagglutinin, the pPICZαC/HAHis6 vector was 
constructed. Template for amplifying the HA sequence 
was derived from H5N1 influenza virus (A/swan/
Poland/305-135V08/2006). Primers were designed to 
produce an anchor-free HA cDNA with extended ends 
that facilitated cloning and yielded a product containing 
the affinity tag. The amplified his- HA sequence fused 
to the heterologous α-mating factor prepro-secretion sig-
nal form S. cerevisiae that directs protein export into the 
medium was ligated into appropriate restriction sites of 
the pPICZαC plasmid. DNA sequencing confirmed cor-
rect orientation of the insert. Following amplification in 
the E. coli DH5α strain, the pPICZαC/HAHis6 plasmid 
was linearized with PmeI and used for transformation of 
P. pastoris KM71 and SMD 1168 strains. Expression of 
the HA gene was induced by the activation of AOX1 
promoter with methanol. P. pastoris transformants grown 
in the methanol-containing BMMY medium started to 
secrete the HA protein. Induction of HA was already 
visible after 24 h, but was potentiated with time, an op-
timum being attained after 5–7 days. Figure 1 shows the 
rHA overexpression in a mean time of induction. SDS/
PAGE followed by Coomassie Brilliant Blue staining in-
dicated that almost 90% of the overexpressed protein 
was secreted into the medium (not shown). Two P. pas-
toris strains were tested for protein expression and KM 
71 strain yielded a higher protein level in comparison 
to that of SMD 1168 (15 mg and 9 mg of total puri-
fied HA protein per liter, respectively). Therefore, this 
strain was selected for further optimization experiments. 
We observed a significant effect of the pH of the ex-
tracellular medium on the protein expression and the 
pH 7.8 was selected for efficient protein production. In 
preliminary experiments, 1% methanol was added every 
24 h until the optimal time of induction was reached. 
Further experiments have shown that a single induction 
with 5% methanol and 7 day cultivation after induction 
yielded the highest rHA level. For purification purposes 
P. pastoris shake-flask culture was scaled up to 400 ml 
BMGY medium and 100 ml of BMMY medium. The 
recombinant protein secreted into the culture medium 
was purified using affinity chromatography under native 
conditions. After one-step purification on the Ni-NTA 
resin the rHA protein was pure when analyzed by SDS/
PAGE (Fig. 2). Typically, 1.3–1.5 mg of recombinant 
antigen was obtained from 100 ml of induced yeast-cul-
ture supernatant.
Characterization of purified rHA
The theoretical molecular weight of His-tagged HA 
lacking C-terminal transmembrane anchor and cyto-
plasmic domain is 59.5 kDa. The molecular weight 
of HA1 and HA2 domains is 39.5 and 20 kDa, re-
spectively. SDS/PAGE analysis has shown that the 
rHA protein expressed in P. pastoris displayed three 
bands with molecular weight about 65, 47 and 22 
kDa (Fig. 2). Two of the higher molecular weight 
bands gave a positive signal in Western blot analy-
sis using anti-His and anti-HA1 antibodies (Fig. 1A 
and B). Mass spectrometry analysis of protein bands 
confirmed the presence of the whole rHA and two 
cleaved subunits. In order to determine whether the 
Figure 1. Western blot analysis of rHA overexpression. 
Protein samples were electrophoresed in 12% SDS/PAGE and 
transferred onto membrane and identified by anti-His (A) and an-
ti-HA1 (B) antibody. A — culture after 70 h of methanol induction. 
Line 1 — 1 ml of culture medium precipitated with TCA. Line 2 — 
cell pellet from 1 ml of culture. B — Ni-NTA column purified rHA, 
line 1 and 2 — about 2 μg of protein eluted consecutively from 
column by 250 mM imidazole. M — protein marker.
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rHA protein is partially cleaved into HA1 and HA2 
subunits, an excess of a reducing agent was added to 
the elution fractions. Under reducing conditions only 
two bands: about 47 and 22 kDa were seen, indicating 
that the whole pool of rHA expressed in P. pastoris is 
cleaved into HA1 and HA2 subunits (Fig. 3).
MS/MS analysis of protein
The difference between the calculated molecular 
weight of rHA and its subunits and the apparent mo-
lecular weight of SDS/PAGE bands indicated pro-
tein modifications. After a reaction with Endo H, the 
molecular weight of about 47 kDa band decreased to 
about 40 kDa (Fig. 4). This shift in molecular weight 
suggests glycosylation of the rHA protein produced in 
P. pastoris. Mass spectrometry analysis confirmed that 
all of the predicted glycosylation sites in HA1 subunit 
are glycosylated (see Table 1).
Glycosylated and truncated rHA elicits a high antibody 
titer
Purified, His-tagged hemagglutinin was tested for 
immunogenicity in a mice model. To determine an 
optimal dose of the antigen, mice were immunized in-
tradermally with three doses of rHA given at 3-week 
intervals. A control group received only adjuvant at 
the same intervals and it did not induce an HA-spe-
cific immune response. After the second, and more 
clearly, after the third antigen injection, a significant 
immune response was detected in mice immunized 
with 1, 5 and 25 μg of rHA (Fig. 5A). Sera samples 
of mice immunized with the lowest antigen dose (1µg) 
show the highest IgG titer reached ca. 1 mln after 
the second booster, however, with a significant scat-
ter. Not surprisingly, the individual response seems to 
normalize with higher antigen doses, i.e. 25 µg. There-
fore, the next immunization series were done with an 
elevated antigen concentration. Titer in the HI assay 
was considered as a preliminary and indirect measure 
of neutralizing antibody response against the rHA an-
tigen. Group immunized with 1 μg of rHA showed a 
maximum of 512 HI titer but only 3 mice out of 5 
were positive. To explore whether the route of immu-
nization affected the efficacy of humoral response in 
mice, the animals were immunized intradermally and 
subcutaneously with 25 μg of rHA. After third immu-
nization, mice immunized subcutaneously showed a 
higher IgG titer (Fig. 5B).
DISCUSSION
Influenza virus is a pathogen inducing respiratory 
disease with symptoms varying from mild to severe. 
Certain strains of the virus could be even lethal to the 
host. The virus recurring epidemics, quite often evolv-
ing into pandemics, are a constant menace to public 
health. Besides humans, the virus spreads among swine, 
horses, and dogs, but mainly in birds, often pointed 
out as the primary host of the pathogen. Until now, 
there are no safe medications against influenza. Effec-
tiveness of a quite recently introduced drug — tami-
flu — is under discussion, and the strains resistant to 
the drug already circulate in the population. A realistic 
barrier against the disease remains therefore by vacci-
nation against influenza. It is well established that the 
virus’ hemagglutinin is the main antigen, in-
ducing neutralizing antibodies. However, 
the HA gene mutates fast and the resulting 
“antigenic drift” necessities constant crea-
tion of novel vaccine versions acting against 
seasonal versions of the pathogen. This is a 
rather compelling task as the standard vac-
cines are prepared from the viruses grown on 
a large scale in chicken embryos. Production 
of the recombinant HA in appropriate ex-
pression systems is an alternative approach. 
Some of such systems were already success-
fully adapted to production of a recombinant 
Figure 2. Purification of rHA by Ni-NTA chromatography. 
M — protein marker, Lane 1 — wash with PBS, Lane 2 to 5 — 
protein eluted with 250 mM imidazole.
Figure 3. Electrophoretic analysis of rHA protein under reducing 
and non-reducing conditions.
Figure 4. Western blot analysis of rHA1 treated with Endo H. 
rHA purified from P. pastoris KM 71 strain was deglycosylated 
with Endo H. 
Protein samples were electrophoresed in 12% SDS/PAGE and 
transferred onto membrane and identified by anti-His ant/ibody.
Table 1. Table represents N-glycosylated peptides from the HA of H5N1 in-
fluenza strain (A/swan/Poland/305-135V08/2006) confirmed by LC/MS anal-
ysis. 
N-linked glycosylation sites are underlined and in bold. In case of 1-22 pep-
tide, two neighboring asparagine residues are modified.
Glycosite Residue Region Amino acid sequence
1 1-22 HA1  HANNSTEQVDTIMEK
2 22-35 HA1  NVTVTHAQDILEK
3 163-189 HA1  SYNNTNQEDLLVLWGIHHPNDAAEQTR
4 278-304 HA1  CQTPIGAINSSMPF
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antigen, useful as a so called “subunit” or “new gen-
eration” vaccine, but have some disadvantages. Produc-
tion in mammalian or insect cell lines (Wu et al., 2010; 
Crawford et al., 1999) is costly, requires high-tech mass 
cell production that is under constant threat of foreign 
pathogen introduction. HA may be overexpresessed in 
E.coli, but the product is insoluble and the purification 
is tedious. Searching for an optimal antigen production 
method we opted for a simple and inexpensive Pichia 
pastoris system. Here, secretion of the overexpressed 
polypeptide considerably facilitates the purification of 
the product. In the literature, there are reported sev-
eral attempts at the production of HA in P. pastoris. 
Full length HA protein of H1 type (Athmaram et al., 
2011; 2012) and H5 type virus (Wang et al., 2007) were 
expressed in P. pastoris as partially secreted, soluble pro-
teins. The level of expressions appeared to be low. Ex-
pression of the H5 type polypeptide was also reported 
by the Subathra group (Subathra et al., 2014) but the 
protein was not exported out of the cells. In the system 
described here, the overproduced protein is secreted up 
to at least 90%, considerably facilitating further purifi-
cation of the antigen. We anticipated that such efficient 
secretion results from the truncation of the sequence 
coding for 16 N-terminal amino acids (signal peptide) 
and the C-terminal transmembrane domain. This HA 
fragment is responsible for anchoring in the cell mem-
brane and its deletion may be beneficial for secretion. 
Our selection of an appropriate producer strain is also 
advantageous. Contrary to the common observations, 
it is not the standard SMD 1168 secreting strain, but 
KM 71 which efficiently secretes the HA antigen. This 
is surprising as in our previous experiments with ex-
pression of several polypeptides, SMD 1168 appeared 
to be an efficient secretion strain (Grzelak et al., 2003; 
Kludkiewicz et al., 2005). An important factor for activ-
ity of HA is its specific cleavage into H1 and H2 subu-
nits (Klenk et al., 1975; Lazarowitz & Choppin, 1975; 
Steinhauer, 1999). In contrast to other reports (Wang 
et al., 2007) the rHA produced in our system is fully 
processed into subunits, without traces of further pro-
teolysis (see Fig. 2). The data presented here demon-
Figure 5. A. HA specific serum IG endpoint titers after mice immunization with P. pastoris rHA. 
Bars represent the average of the titers in sera collected separately from 5 individuals. For each bar, the range of scattering is indicated. 
The endpoint titer is defined as the highest dilution of serum yielding in ELISA test absorbance 4 times over background. B. Evaluation 
of the route of antigen administration. Mice were injected with 25 μg doses of rHA antigen either subcutaneously (s.c) or intradermally 
(i.d.).
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strate that the influenza antigen produced in P. pastoris 
with good efficiency is highly immunogenic and might 
be consider as a candidate for a subunit vaccine.
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